Incyte
INCY
#1190
Rank
NZ$33.81 B
Marketcap
NZ$169.89
Share price
0.27%
Change (1 day)
32.02%
Change (1 year)

Revenue for Incyte (INCY)

Revenue in 2024: NZ$7.52 Billion

According to Incyte's latest financial reports the company's current revenue (TTM ) is NZ$8.08 Billion. In 2024 the company made a revenue of NZ$7.52 Billion an increase over the revenue in the year 2023 that were of NZ$5.84 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Incyte from 1996 to 2024

Annual revenue

Year Revenue Change
2024NZ$7.52 B28.69%
2023NZ$5.84 B9.3%
2022NZ$5.34 B22.29%
2021NZ$4.37 B18.3%
2020NZ$3.69 B15.3%
2019NZ$3.20 B14.25%
2018NZ$2.80 B29.7%
2017NZ$2.16 B35.51%
2016NZ$1.59 B44.94%
2015NZ$1.10 B68.7%
2014NZ$0.65 B51.14%
2013NZ$0.43 B19.61%
2012NZ$0.36 B198.37%
2011NZ$0.12 B-45.04%
2010NZ$0.22 B1626.2%
2009NZ$12.75 M88.84%
2008NZ$6.75 M-84.98%
2007NZ$44.96 M14.58%
2006NZ$39.23 M241.79%
2005NZ$11.48 M-23.93%
2004NZ$15.09 M-79.17%
2003NZ$72.44 M-62.69%
2002NZ$0.19 B-63.23%
2001NZ$0.52 B20.51%
2000NZ$0.43 B45.8%
1999NZ$0.30 B17.48%
1998NZ$0.25 B66.41%
1997NZ$0.15 B164.23%
1996NZ$58.17 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Novartis
NVS
NZ$95.21 B 1,077.49%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
NZ$105.48 B 1,204.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$99.83 B 1,134.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$60.43 B 647.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Ligand Pharmaceuticals
LGND
NZ$0.42 B-94.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Geron
GERN
NZ$0.30 B-96.19%๐Ÿ‡บ๐Ÿ‡ธ USA
CTI BioPharma
CTIC
NZ$0.12 B-98.43%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ$0.15 B-98.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Ardelyx
ARDX
NZ$0.66 B-91.73%๐Ÿ‡บ๐Ÿ‡ธ USA